MARKET

RPRX

RPRX

Royalty Pharma plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.09
-0.18
-0.45%
Closed 19:06 10/20 EDT
OPEN
40.92
PREV CLOSE
40.27
HIGH
41.49
LOW
40.05
VOLUME
2.30M
TURNOVER
--
52 WEEK HIGH
56.50
52 WEEK LOW
38.54
MARKET CAP
23.87B
P/E (TTM)
12.66
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Royalty Pharma to Announce Third-Quarter 2020 Financial Results on November 11, 2020
NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call InformationThe conference call can be accessed live over the phone by dialling (833) 519-1253, or for international callers by dialling (914) 800-3826. The passcode to access the conference call is 8067315.A live webcast may be accessed from the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.About Royalty PharmaFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates.Royalty Pharma Investor Relations and Communications+1 (212) 883-2295 ir@royaltypharma.com
GlobeNewswire · 1d ago
Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering. The selling shareholders are expected to grant the underwriters an option to purchase up to 2,601,455 additional Class A ordinary shares. The Company will not receive any of the proceeds from the sale of its Class A ordinary shares by the selling shareholders. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs & Co. LLC and Citigroup are acting as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Cowen, Evercore ISI, Truist Securities and UBS Investment Bank are also acting as joint book-running managers for the offering.This offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to the proposed public offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014.A registration statement on Form S-1 relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Royalty PharmaFounded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and three development-stage product candidates.Forward-Looking StatementsThis press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.Royalty Pharma Investor Relations and Communications +1 (212) 883-0200 ir@royaltypharma.com
GlobeNewswire · 10/13 21:10
New Ventures Funds Rebrands as Scientia Ventures
New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com. This reflects the broadening of the firm's strategic direction since launching its 3rd fund in 2017 to reflect its focus on transformational
PR Newswire · 10/02 11:00
Royalty Pharma plc (NASDAQ:RPRX) Shares Could Be 41% Below Their Intrinsic Value Estimate
Does the September share price for Royalty Pharma plc (NASDAQ:RPRX) reflect what it's really worth? Today, we will...
Simply Wall St. · 09/16 16:42
Royalty Pharma Declares Third-Quarter 2020 Dividend
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2020 of $0.15 per class A share. The dividend will be paid on September 30, 2020, to shareholders of record at the close of business
GlobeNewswire · 09/02 13:00
Coronavirus update: U.S. death toll tops 177,000 as FDA head acknowledges he misspoke on convalescent plasma
The U.S. death toll from the coronavirus illness COVID-19 climbed above 177,000 on Tuesday, as experts continued to question claims made about the use of...
marketwatch.com · 08/25 17:57
Royalty Pharma prices $6 billion bond deal that is its first as a public company
Royalty Pharma PLC undefined priced a $6 billion bond offering on Tuesday, joining the many companies issuing record levels of debt during the pandemic. The...
MarketWatch · 08/25 13:14
Royalty Pharma Announces Pricing of $6.0 Billion Senior Unsecured Notes
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): * $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; * $1 billion
GlobeNewswire · 08/25 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RPRX. Analyze the recent business situations of Royalty Pharma plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RPRX stock price target is 52.29 with a high estimate of 56.00 and a low estimate of 47.00.
EPS
Institutional Holdings
Institutions: 119
Institutional Holdings: 147.76M
% Owned: 24.82%
Shares Outstanding: 595.38M
TypeInstitutionsShares
Increased
0
0
New
119
147.76M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/Chief Executive Officer/Director
Pablo Legorreta
Vice Chairman/Executive Vice President/Director
Christopher Hite
Chief Financial Officer/Executive Vice President
Terrance Coyne
Executive Vice President/General Counsel
George Lloyd
Executive Vice President
James Reddoch
Senior Vice President
Molly Chiaramonte
Senior Vice President
Marshall Urist
Director
Bonnie Bassler
Director
M. Germano Giuliani
Director
Rory Riggs
Independent Director
Errol De Souza
Independent Director
Catherine Engelber
Independent Director
Henry Fernandez
Independent Director
William Ford
Independent Director
Ted Love
Independent Director
Gregory Norden
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/15/2020
Dividend USD 0.15
11/19/2020
09/02/2020
Dividend USD 0.15
09/14/2020
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RPRX
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in approximately 45 commercial products and four development-stage product candidates.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Royalty Pharma plc stock information, including NASDAQ:RPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPRX stock methods without spending real money on the virtual paper trading platform.